The oncologic results of cryoablation in prostate cancer patients with bone metastases

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–86.
   PubMed Web of Science ®Google Scholar
• Culp SH, Schellhammer PF, Williams MB. (2014). Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based Study. Eur Urol 65:1058–66.
   PubMed Web of Science ®Google Scholar
• Gratzke C, Engel J, Stief CG. (2014). Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol 66:602–3.
   PubMed Web of Science ®Google Scholar
• Satkunasivam R, Kim AE, Desai M, et al. (2015). Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis. J Urol 194:378–85.
   PubMed Web of Science ®Google Scholar
• Babaian RJ, Donnelly B, Bahn D, et al. (2008). Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 180:1993–2004.
   PubMed Web of Science ®Google Scholar
• Guo Z, Si T, Yang X, Xu Y. (2015). Oncological outcomes of cryosurgery as primary treatment in T3 prostate cancer: experience of a single centre. BJU Int 116:79–84.
   PubMed Web of Science ®Google Scholar
• Chin JL, Ng CK, Touma NJ, et al. (2008). Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. Prostate Cancer Prostatic Dis 11:40–5.
   PubMed Web of Science ®Google Scholar
• Chin JL, Al-Zahrani AA, Autran-Gomez AM, et al. (2012). Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b). J Urol 188:1170–5.
   PubMed Web of Science ®Google Scholar
• Donnelly BJ, Saliken JC, Brasher PM, et al. (2010). A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 116:323–30.
   PubMed Web of Science ®Google Scholar
• Frohmüller HG, Theiss M, Manseck A, Wirth MP. (1995). Survival and quality of life of patients with stage D1 (T1-3 pN1-2M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone. Eur Urol 27:202–6.
   PubMed Web of Science ®Google Scholar
• Engel J, Bastian PJ, Baur H, et al. (2010). Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 57:754–61.
   PubMedGoogle Scholar
• Gakis G, Boorjian SA, Briganti A, et al. (2014). The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. Eur Urol 66:191–9.
   PubMed Web of Science ®Google Scholar
• Roberts CB, Jang TL, Shao YH, et al. (2011). Treatment profile and complications associated with cryotherapy for localized prostate cancer: a population-based study. Prostate Cancer Prostatic Dis 14:313–9.
   PubMed Web of Science ®Google Scholar
• Marien A, Gill I, Ukimura O, et al. (2014). Target ablation-image-guided therapy in prostate cancer. Urol Oncol 32:912–23.
   PubMed Web of Science ®Google Scholar
• Peters M, Moman MR, van der Poel HG, et al. (2013). Patterns of outcome and toxicity after salvage prostatectomy, salvage cryoablation and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review. World J Urol 31:403–9.
   PubMed Web of Science ®Google Scholar
• Kongnyuy M, Berg CJ, Kosinski KE, et al. (2017). Salvage focal cryosurgery may delay use of androgen deprivation therapy in cryotherapy and radiation recurrent prostate cancer patients. Int J Hyperthermia 29:1–4.
   Google Scholar
• Schiavina R, Borghesi M, Brunocilla E, et al. (2013). Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: identifcation of risk categories according to number of positive nodes and Gleason score. BJU Int 111:1237–44.
   PubMed Web of Science ®Google Scholar
• Fossati N, Trinh QD, Sammon J, et al. (2015). Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: A SEER-based Study. Eur Urol 67:3–6.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Pfister D, Porres D. (2015). Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol 193:832–8.
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Mason MD, et al. (2012). Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. Lancet Oncol 13:549–58.
   PubMed Web of Science ®Google Scholar
• Koo KC, Park SU, Kim KH, et al. (2015). Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levels. Prostate Int 3:10–5.
   PubMed Web of Science ®Google Scholar
• Sverrisson EF, Nguyen H, Kim T, Pow-Sang JM. (2014). Primary cryoablation for clinically localized prostate cancer–do perioperative tumor characteristics correlate with post-treatment biopsy results? Urology 83:376–8.
   PubMed Web of Science ®Google Scholar
• Tzelepi V, Efstathiou E, Wen S, et al. (2011). Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 29:2574–81.
   PubMed Web of Science ®Google Scholar
• Grossgold E, Given R, Ruckle H, Jones JS. (2014). Does neoadjuvant androgen deprivation therapy before primary whole gland cryoablation of the prostate affect the outcome? Urology 83:379–83.
   PubMed Web of Science ®Google Scholar
• Si TG, Wang JP, Guo Z. (2013). Analysis of circulating regulatory T cells (CD4 + CD25 + CD127-) after cryosurgery in prostate cancer. Asian J Androl 15:461–5.
   PubMed Web of Science ®Google Scholar
• MD Anderson Cancer Center Best systemic therapy or best systemic therapy (BST) plus definitive treatment (radiation or surgery) [identifier NCT01751438]. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/show/NCT01751438.
   Google Scholar
• Won AC, Gurney H, Marx G, et al. (2013). Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int 112:E250–5.
   PubMed Web of Science ®Google Scholar